Drogeninduzierte Psychosen

Substanzkonsumstörungen und Psychosen stehen häufig in einem kausalen Zusammenhang. Dieser kann uni- oder bidirektional sein – oder beide Störungen beruhen auf gemeinsamen ätiopathogenetischen Faktoren. Substanzen wie Cannabinoide, Stimulanzien oder Halluzinogene scheinen wichtige Ko-Faktoren für die Entwicklung einer (sekundären) Psychose darzustellen. Der Beitrag gibt einen Überblick über die Substanzgruppen, Diagnostik und Therapie.

Abstract

Substance use disorders and psychoses are often causally related. This causal relationship can be uni- or bidirectional – or both disorders are based on common etiopathogenetic factors. Substances such as cannabinoids, stimulants or hallucinogens seem to be important cofactors for development of a (secondary) psychosis. This article gives an overview of substance groups, diagnostics and therapy.

Key words

substance use disorders - substance-induced psychoses - cannabinoids - stimulants - hallucinogens

Schlüsselwörter

Substanzkonsumstörungen - substanzinduzierte Psychosen - Cannabinoide - Stimulanzien - Halluzinogene

Publication History

Article published online:
08 November 2022

• Literatur

• 1 Regier DA, Farmer ME, Rae DS. et al. Comorbidity of mental dis-orders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511-2518
• 2 Moggi F.. Doppeldiagnosen. Komorbidität psychischer Störungen und Sucht. Bern: Huber; 2007
• 3 Gage SH, Hickman M, Zam mit S.. Association between cannabis and psychosis: Epidemiologic evidence. Biol Psychiatry 2016; 79: 549-556
• 4 DGPPN e.V. für die Leitliniengruppe: S3-Leitlinie Schizophrenie. 2019: verfügbar unter (zuletzt geändert am 15.03.2019) https://www.awmf.org/leitlinien/detail/ll/038-009.html
• 5 Gouzoulis-Mayfrank E.. Psychotische Störungen und komorbide Suchterkrankungen. Walter M, Gouzoulis-Mayfrank E. Psychische Störungen und Suchterkrankungen. Stuttgart: Kohlhammer; 2019: 103-117
• 6 Beckmann D, Lowman KL, Nargiso J. et al. Substance-induced psychosis in youth. Child Adolesc Psychiatr Clin N Am 2020; 29: 131-143
• 7 Weibell MA, Joa I, Bramness J. et al. Treated incidence and baseline characteristics of substance induced psychosis in a Norwegian catchment area. BMC Psychiatry 2013; 13: 319
• 8 Thompson A, Marwaha S, Winsper C. et al. Short-term outcome of substanceinduced psychotic disorder in a large UK first episode psychosis cohort. Acta Psychiatr Scand 2016; 134: 321-328
• 9 O’Connell J, Sunwoo M, McGorry P. et al. Characteristics and outcomes of young people with substance induced psychotic disorder. Schizophr Res 2019; 206: 257-262
• 10 Fraser S, Hides L, Philips L. et al. Differentiating first episode substance induced and primary psychotic disorders with concurrent substance use in young people. Schizophr Res 2012; 136: 110-115
• 11 Dawe S, Geppert L, Occhipinti S. et al. A comparison of the symptoms and shortterm clinical course in inpatients with substance-induced psychosis and primary psychosis. J Subst Abuse Treat 2011; 40: 95-101
• 12 Rugani F, Bacciardi S, Rovai L. et al. Symptomatological features of patients with and without Ecstasy use during their first psychotic episode. Int J Environ Res Public Health 2012; 9: 2283-2292
• 13 Hoch E, Friemel CM, Schneider M.. Cannabis: Potenzial und Risiko – Eine wissenschaftliche Bestandsaufnahme. Berlin, Heidelberg: Springe; 2019
• 14 Leweke FM, Piomelli D, Pahlisch F. et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012; 2: e94
• 15 Fiorentini A, Volonteri LS, Dragogna F. et al. Substance-induced psychoses: a critical review of the literature. Curr Drug Abuse Rev 2011; 4: 228-240
• 16 Atzendorf J, Rauschert C, Seitz NN. et al. The use of alcohol, tobacco, illegal drugs and medicines – an estimate of consumption and substance-related disorders in Germany. Dtsch Arztebl Int 2019; 116: 577-584
• 17 French ED.. delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett 1997; 226: 159-162
• 18 Gessa GL, Melis M, Muntoni AL. et al. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 1998; 341: 39-44
• 19 Bossong MG, van Berckel BN, Boellaard R. et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacol 2009; 34: 759-766
• 20 Kuepper R, Ceccarini J, Lataster J. et al. Delta-9-tetrahydrocannabinol-induced dopamine release as a function of psycho-sis risk: 18F-fallypride positron emission tomography study. PLoS One 2013; 8: e70378
• 21 ElSohly MA, Mehmedic Z, Foster S. et al. Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry 2016; 79: 613-619
• 22 Di Forti M, Quattrone D, Freeman TP. et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry 2019; 6: 427-436
• 23 Fattore L.. Synthetic cannabinoids-further evidence supporting the relationship between cannabinoids and psychosis. Biol Psychiatry 2016; 79: 539-548
• 24 Bramness JG, Rognli EB.. Psychosis induced by amphetamines. Curr Opin Psychiatry 2016; 29: 236-241
• 25 Drogenbeauftragte der Bundesregierung, Bundesministerium für Gesundheit (BMG), Bundesärztekammer (BÄK), Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN). S3-Leitlinie Methamphetamin-bezogene Störungen. 2016: Verfügbar unter https://www.aezq.de/mdb/edocs/pdf/literatur/s3-llmethamphetamin-bezogene-stoerungen-lang.pdf
• 26 Orsolini L, Papanti GD, De Berardis D. et al. The “endless trip” among the NPS users: psychopathology and psychopharmacology in the hallucinogenpersisting perception disorder. A systematic review. Front Psychiatry 2017; 8: 240
• 27 DGPPN, Referat Notfallpsychiatrie. S2k-Leitlinie Notfallpsychiatrie (Stand: 13.04.2019) AWMF-Registernummer: 038-023. verfügbar unter https://www.awmf.org/uploads/tx_szleitlinien/038-023l_S2k_Notfallpsychiatrie_2019-05_1.pdf
• 28 Adorjan K, Pogarell O.. Psychische Komorbiditäten. Falkai P, Hasan A. Praxishandbuch Schizophrenie – Diagnostik-Therapie-Versorgungsstrukturen. München: Elsevier; 2020: 50-69